Advanced search
Publication Cover
Expert Review of Hematology Volume 6, 2013 - Issue 1
Submit an article Journal homepage
399
Views
89
CrossRef citations to date
0
Altmetric
Perspective

Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis

Richard T Silver Myeloproliferative Disease Center, Division of Hematology–Oncology, Weill Cornell Medical Center, New York, NY, USA. [email protected]; Myeloproliferative Disease Center, Division of Hematology–Oncology, Weill Cornell Medical Center, New York, NY, USA. [email protected]
,
Jean-Jacques Kiladjian AP-HP, Hôpital Saint-Louis, Centre d’Investigations Cliniques, 1 avenue Claude Vellefaux, Paris, France; Université Paris Diderot, Paris, France; AP-HP, Hôpital Saint-Louis, Centre d’Investigations Cliniques, 1 avenue Claude Vellefaux, Paris, France; Université Paris Diderot, Paris, France
&
Hans Carl Hasselbalch Department of Hematology, Roskilde Hospital, University of Copenhagen, Copenhagen, Denmark; Department of Hematology, Roskilde Hospital, University of Copenhagen, Copenhagen, Denmark
Pages 49-58 | Published online: 10 Jan 2014

References

  • Kiladjian JJ, Chomienne C, Fenaux P. Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia 22(11), 1990–1998 (2008).
  • Hasselbalch HC, Larsen TS, Riley CH, Jensen MK, Kiladjian JJ. Interferon-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives. Curr. Drug Targets 12(3), 392–419 (2011).
  • Hasselbalch HC. A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Rev. Hematol. 4(6), 637–655 (2011).
  • Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood 117(18), 4706–4715 (2011).
  • Chawla-Sarkar M, Lindner DJ, Liu YF et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8(3), 237–249 (2003).
  • Tabibzadeh S, Sun XZ, Kong QF, Kasnic G, Miller J, Satyaswaroop PG. Induction of a polarized micro-environment by human T cells and interferon-γ in three-dimensional spheroid cultures of human endometrial epithelial cells. Hum. Reprod. 8(2), 182–192 (1993).
  • Albini A, Marchisone C, Del Grosso F et al. Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: a gene therapy approach. Am. J. Pathol. 156(4), 1381–1393 (2000).
  • Selleri C, Maciejewski JP, Sato T, Young NS. Interferon-γ constitutively expressed in the stromal microenvironment of human marrow cultures mediates potent hematopoietic inhibition. Blood 87(10), 4149–4157 (1996).
  • Bukowski RM, Tendler C, Cutler D, Rose E, Laughlin MM, Statkevich P. Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-α-2b formulation. Cancer 95(2), 389–396 (2002).
  • Kuriakose E, Vandris K, Wang YL et al. Decrease in JAK2V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera. Haematologica 97(4), 538–542 (2012).
  • Yanai Y, Sanou O, Kayano T et al. Analysis of the antiviral activities of natural IFN-α preparations and their subtype compositions. J. Interferon Cytokine Res. 21(10), 835–841 (2001).
  • Singal AK, Jampana SC, Anand BS. Peg-interferon α-2a is superior to peg-interferon α-2b in the treatment of naive patients with hepatitis C virus infection: meta-analysis of randomized controlled trials. Dig. Dis. Sci. 56(8), 2221–2226 (2011).
  • Michallet M, Maloisel F, Delain M et al.; PEG-Intron CML Study Group. Pegylated recombinant interferon α-2b vs recombinant interferon α-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a Phase III study. Leukemia 18(2), 309–315 (2004).
  • Lipton JH, Khoroshko N, Golenkov A et al.; Pegasys CML Study Group. Phase II, randomized, multicenter, comparative study of peginterferon-α-2a (40 kD) (Pegasys) versus interferon α-2a (Roferon-A) in patients with treatment-naive, chronic-phase chronic myelogenous leukemia. Leuk. Lymphoma 48(3), 497–505 (2007).
  • Lu M, Zhang W, Li Y et al. Interferon-α targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway. Exp. Hematol. 38(6), 472–480 (2010).
  • Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J. Clin. Oncol. 29(5), 573–582 (2011).
  • Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am. J. Hematol. 87(3), 285–293 (2012).
  • Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood 100(13), 4272–4290 (2002).
  • Spivak JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood 112(2), 231–239 (2008).
  • Cassinat B, Laguillier C, Gardin C et al.; PV-Nord Group. Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass? Leukemia 22(2), 452–453 (2008).
  • Silver RT, Chow W, Vandris K et al. Prospective evaluation of the world health organization criteria for the diagnosis of polycythemia vera. Presented at: The 53rd Annual ASH Annual Meeting and Exposition. Abstract 3837. San Diego, CA, USA, 10–13 December 2011.
  • Johansson PL, Safai-Kutti S, Kutti J. An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: a study of patients with polycythaemia vera and apparent polycythaemia. Br. J. Haematol. 129(5), 701–705 (2005).
  • Mossuz P, Girodon F, Donnard M et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica 89(10), 1194–1198 (2004).
  • Alvarez-Larrán A, Ancochea A, Angona A et al. Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia. Haematologica 97(11), 1704–1707 (2012).
  • Pearson TC, Guthrie DL, Simpson J et al. Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology. Br. J. Haematol. 89(4), 748–756 (1995).
  • Silver RT. Recombinant interferon-α for treatment of polycythaemia vera. Lancet 2(8607), 403 (1988).
  • Bellucci S, Harousseau JL, Brice P, Tobelem G. Treatment of essential thrombocythaemia by α 2a interferon. Lancet 2(8617), 960–961 (1988).
  • Linkesch W, Gisslinger H, Ludwig H, Flener R, Sinzinger H. [Therapy with interferon (recombinant IFN-α-2C) in myeloproliferative diseases with severe thrombocytoses]. Acta Med. Austriaca 12(5), 123–127 (1985).
  • Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-α. Cancer 107(3), 451–458 (2006).
  • Larsen TS, Møller MB, de Stricker K et al. Minimal residual disease and normalization of the bone marrow after long-term treatment with α-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission. Hematology 14(6), 331–334 (2009).
  • Silver RT, Vandris K. Recombinant interferon α (rIFN α-2b) may retard progression of early primary myelofibrosis. Leukemia 23(7), 1366–1369 (2009).
  • Silver RT, Vandris K, Goldman JJ. Recombinant interferon-a may retard progression of early primary myelofibrosis: a preliminary report. Blood 117(24), 6669–6672 (2011).
  • Kiladjian JJ, Cassinat B, Turlure P et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon α-2a. Blood 108(6), 2037–2040 (2006).
  • Di Nisio M, Barbui T, Di Gennaro L et al.; European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP) Investigators. The haematocrit and platelet target in polycythemia vera. Br. J. Haematol. 136(2), 249–259 (2007).
  • Turlure P, Cambier N, Roussel M et al. Complete hematological, molecular and histological remissions without cytoreductive treatment lasting after pegylated-interferon {α}-2a (peg-IFN{α}-2a) therapy in polycythemia vera (PV): long term results of a Phase 2 trial. Blood (ASH Annual Abstracts) 118(21), 280 (2011).
  • Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin. Hematol. 23(2), 132–143 (1986).
  • Marchioli R, Finazzi G, Specchia G et al. Cardiovascular events and intensity of treatment in polycythemia vera. N. Engl. J. Med. 368, 22–23 (2013).
  • Berlin NI. Treatment of the myeloproliferative disorders with 32P. Eur. J. Haematol. 65(1), 1–7 (2000).
  • Berk PD, Goldberg JD, Silverstein MN et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N. Engl. J. Med. 304(8), 441–447 (1981).
  • Najean Y, Rain JD. The very long-term evolution of polycythemia vera: an analysis of 318 patients initially treated by phlebotomy or 32P between 1969 and 1981. Semin. Hematol. 34(1), 6–16 (1997).
  • Fretham SJ, Carlson ES, Georgieff MK. The role of iron in learning and memory. Adv. Nutr. 2(2), 112–121 (2011).
  • Avni T, Leibovici L, Gafter-Gvili A. Iron supplementation for the treatment of chronic heart failure and iron deficiency: systematic review and meta-analysis. Eur. J. Heart Fail. 14(4), 423–429 (2012).
  • Balci K, Utku U, Asil T, Büyükkoyuncu N. Deep cerebral vein thrombosis associated with iron deficiency anaemia in adults. J. Clin. Neurosci. 14(2), 181–184 (2007).
  • Spivak JL. An inconvenient truth. Blood 115(14), 2727–2728 (2010).
  • Spivak JL, Hasselbalch H. Hydroxycarbamide: a user’s guide for chronic myeloproliferative disorders. Expert Rev. Anticancer Ther. 11(3), 403–414 (2011).
  • Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J. Clin. Oncol. 29(29), 3907–3913 (2011).
  • Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence of allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 22(7), 1299–1307 (2008).
  • Tefferi A. Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices. Leuk. Lymphoma 51(4), 576–582 (2010).
  • Silver RT, Vandris K, Wang YL et al. JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. Leuk. Res. 35(2), 177–182 (2011).
  • Quintás-Cardama A, Kantarjian H, Manshouri T et al. Pegylated interferon α-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J. Clin. Oncol. 27(32), 5418–5424 (2009).
  • Kiladjian JJ, Cassinat B, Chevret S et al. Pegylated interferon-α-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 112(8), 3065–3072 (2008).
  • Jones AV, Silver RT, Waghorn K et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood 107(8), 3339–3341 (2006).
  • Samuelsson J, Mutschler M, Birgegård G, Gram-Hansen P, Björkholm M, Pahl HL. Limited effects on JAK2 mutational status after pegylated interferon α-2b therapy in polycythemia vera and essential thrombocythemia. Haematologica 91(9), 1281–1282 (2006).
  • Kiladjian JJ, Massé A, Cassinat B et al.; French Intergroup of Myeloproliferative Neoplasms (FIM). Clonal analysis of erythroid progenitors suggests that pegylated interferon α-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells. Leukemia 24(8), 1519–1523 (2010).
  • Barbui T, Finazzi G, Carobbio A et al. Development and validation of an International Prognostic Score of thrombosis in WHO-Essential Thrombocythemia (IPSET-thrombosis). Blood 120(26), 5128–5133 (2012).
  • Girodon F, Dutrillaux F, Broséus J et al. Leukocytosis is associated with poor survival but not with increased risk of thrombosis in essential thrombocythemia: a population-based study of 311 patients. Leukemia 24(4), 900–903 (2010).
  • Campbell PJ, Bareford D, Erber WN et al. Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J. Clin. Oncol. 27(18), 2991–2999 (2009).
  • Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin. Proc. 81(2), 159–166 (2006).
  • Passamonti F, Rumi E, Arcaini L et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica 93(11), 1645–1651 (2008).
  • Radaelli F, Colombi M, Calori R et al. Analysis of risk factors predicting thrombotic and/or haemorrhagic complications in 306 patients with essential thrombocythemia. Hematol. Oncol. 25(3), 115–120 (2007).
  • Johansson P, Mesa R, Scherber R et al. Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms. Leuk. Lymphoma 53(3), 441–444 (2012).
  • Roy L, Ianotto JC, Guilhot J et al. Pegylated interferon α-2a therapy for patients with high risk essential thrombocythemia: a retrospective analysis on 59 patients. on behalf of the French Intergroup of Myeloproliferative Disorders (FIM). Blood 116(21), a1974 (2010).
  • Cervantes F, Alvarez-Larrán A, Talarn C, Gómez M, Montserrat E. Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br. J. Haematol. 118(3), 786–790 (2002).
  • Barbui T, Thiele J, Passamonti F et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J. Clin. Oncol. 29(23), 3179–3184 (2011).
  • Lengfelder E, Griesshammer M, Hehlmann R. Interferon-α in the treatment of essential thrombocythemia. Leuk. Lymphoma 22(Suppl. 1), 135–142 (1996).
  • Hasselbalch HC. Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment? Leuk. Res. 33(1), 11–18 (2009).
  • Hasselbalch HC, Kiladjian JJ, Silver RT. Interferon α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. J. Clin. Oncol. 29(18), e564–e565 (2011).
  • Ianotto JC, Kiladjian JJ, Demory JL et al. PEG-IFN-α-2a therapy in patients with myelofibrosis: a study of the French Groupe d’Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myéloprolifératifs (FIM). Br. J. Haematol. 146(2), 223–225 (2009).
  • Robinson S, Bewley S, Hunt BJ, Radia DH, Harrison CN. The management and outcome of 18 pregnancies in women with polycythemia vera. Haematologica 90(11), 1477–1483 (2005).
  • Harrison C. Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. Br. J. Haematol. 129(3), 293–306 (2005).
  • Passamonti F, Randi ML, Rumi E et al. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2(617V>F) mutation. Blood 110(2), 485–489 (2007).
  • Tulpule S, Bewley S, Robinson SE, Radia D, Nelson-Piercy C, Harrison CN. The management and outcome of four pregnancies in women with idiopathic myelofibrosis. Br. J. Haematol. 142(3), 480–482 (2008).
  • Vantroyen B, Vanstraelen D. Management of essential thrombocythemia during pregnancy with aspirin, interferon α-2a and no treatment. A comparative analysis of the literature. Acta Haematol. 107(3), 158–169 (2002).
  • Elliott MA, Tefferi A. Thrombocythaemia and pregnancy. Best Pract. Res. Clin. Haematol. 16(2), 227–242 (2003).
  • Melillo L, Tieghi A, Candoni A et al. Outcome of 122 pregnancies in essential thrombocythemia patients: a report from the Italian registry. Am. J. Hematol. 84(10), 636–640 (2009).
  • Aliverti V, Bonanomi L, Giavini E. Hydroxyurea as a reference standard in teratological screening. Comparison of the embryotoxic and teratogenic effects following single intraperitoneal or repeated oral administrations to pregnant rats. Arch. Toxicol. Suppl. 4, 239–247 (1980).
  • Rumi E, Harutyunyan A, Elena C et al. Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm. Am. J. Hematol. 86(12), 974–979 (2011).
  • Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood 119(14), 3219–3225 (2012).
  • Barbui T, Thiele J, Passamonti F et al. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood 119(10), 2239–2241 (2012).
  • Frederiksen H, Farkas DK, Christiansen CF, Hasselbalch HC, Sørensen HT. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood 118(25), 3219–3225 (2012).
  • Samuelsson J, Hasselbalch H, Bruserud O et al.; Nordic Study Group for Myeloproliferative Disorders. A Phase II trial of pegylated interferon α-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. Cancer 106(11), 2397–2405 (2006).
  • Gowin K, Thapaliya P, Samuelson J et al. Experience with pegylated interferon a-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients. Haematologica 97(10), 1570–1573 (2012).
  • Finazzi G. How to manage essential thrombocythemia. Leukemia 26(5), 875–882 (2012).
  • Beer PA, Erber WN, Campbell PJ, Green AR. How I treat essential thrombocythemia. Blood 117(5), 1472–1482 (2011).
  • Bracarda S, Eggermont AM, Samuelsson J. Redefining the role of interferon in the treatment of malignant diseases. Eur. J. Cancer 46(2), 284–297 (2010).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.